
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is a well-positioned clinical-stage biopharmaceutical company with a strong focus on developing and commercializing therapeutics for prevalent retinal diseases. TH103 has the potential to generate significant revenue and the company's optimized manufacturing process should help to ensure a competitive advantage. While competition in the market is a potential concern, Kalaris has shown promise in treating other retinal diseases, positioning them for long-term success and potential growth in the industry.
Bears say
Kalaris Therapeutics is facing strong competition in the wet AMD treatment market, but its TH103 anti-VEGF therapy shows promising results in preclinical studies. The company has enough funding to support its development until 2027, but there is a need for more durable treatments in wet AMD management. While gene therapy and ocular implants are potential options, Beovu's serious side effects and concerns about ocular implant safety are causing issues in the market.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares